Industry leader to steer ambitious sample management business

Global sample stability and biospecimen storage company Astoriom has appointed Lori A. Ball as its new Chief Executive Officer. The announcement follows the company's acquisition by Limerston Capital and subsequent rebranding earlier this year, underlining its ambitious plans for global expansion and business growth. 

With executive experience and leadership accomplishments in the global sample management and life sciences R&D sector, Lori Ball has an extensive background in commercial strategy and growth, mergers and acquisitions, and executive development.  Prior to joining Astoriom, Lori was President and Chief Executive Officer at StageBio, a histology, pathology, image analysis and specimen archiving services provider for the biopharmaceutical, medical device and contract research industry.  

Additionally, she was Chief Operating Officer at BioIVT, a world-leader in providing preclinical and clinical biological specimens to the industry and research sector as well as the President and Chief Operating Officer at BioStorage Technologies, Inc., now Azenta. At BioStorage Technologies, Inc., Ball pioneered the growth of the venture-capital backed company to a global brand leader in sample management which led to a successful acquisition of the company by Brooks Life Sciences. She also served as the Global Head of Sales, Supply Chain Operations and Commercial Operations for Covance Central Laboratories (acq. Labcorp). 

She joins Astoriom at a stage when its services and expansion areas align with the projected growth of the pharmaceutical stability and storage market and the sector’s evolving customer needs for high-quality biospecimen storage options for scientific asset protection.  

 “I continue to be impressed with the service reputation that Astoriom holds in the industry. Clearly, the confidence that clients have in us will propel our vision to grow our service offerings and our geographical presence. I find this hugely compelling and am thrilled to be joining the team for what marks a new chapter of success for the business," said Lori Ball.

“Astoriom is well-regarded in the market for its commitment to quality and exceptional service to its customers, many of whom are sector leaders themselves.” 

Joao Rosa, Limerston Capital founding partner and Astoriom board member, said: "Lori's appointment reflects our commitment to realizing Astoriom’s full potential and represents a strategic investment in its future.  

“As a seasoned operator with international expertise, her leadership will be pivotal in enhancing our presence in high-value pharmaceutical, biologic, and medical device markets, benefiting both our team and our clients. We are pleased to welcome her on board.” 

More information online